Evidence map›Paper›PMID 34193920›Full record

ArticleScientific reports2021

Identification of natural product modulators of Merkel cell carcinoma cell growth and survival.

Emily A Smith, Natasha T Hill, Tara Gelb, Khalid A Garman, Ekaterina I Goncharova, Heidi R Bokesch, Chang-Kwon Kim, Karen L Wendt, Robert H Cichewicz, Kirk R Gustafson and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Chemoreactive 2,5-Diketopiperazines from aJournal of natural products · 2024
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Emily A SmithMolecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA.
Natasha T HillDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 20891, USA.
Tara GelbDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 20891, USA.
Khalid A GarmanDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 20891, USA.
Ekaterina I GoncharovaMolecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA.
Heidi R BokeschMolecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA.
Chang-Kwon KimMolecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA.
Karen L WendtNatural Products Discovery Group, Department of Chemistry & Biochemistry, Institute for Natural Products Applications and Research Technologies, University of Oklahoma, Norman, OK, 73019, USA.
Robert H CichewiczNatural Products Discovery Group, Department of Chemistry & Biochemistry, Institute for Natural Products Applications and Research Technologies, University of Oklahoma, Norman, OK, 73019, USA.
Kirk R GustafsonMolecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA.
Isaac BrownellDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 20891, USA.
Curtis J HenrichMolecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA. henrichcj@mail.nih.gov.
National Institute of Arthritis and Musculoskeletal and Skin Diseases · USNational Cancer Institute · USFrederick National Laboratory for Cancer Research · USUniversity of Oklahoma · USTarget (United States) · US

Funding

Molecular pathogenesis of Merkel cell carcinomaZIABC011394 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BROWNELL, ISAAC · 2011 to 2021
$6.8M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Merkel cell carcinoma (MCC) is a rare, but aggressive skin cancer the incidence of which has increased significantly in recent years. The majority of MCCs have incorporated Merkel cell polyomavirus (VP-MCC) while the remainder are virus-negative (VN-MCC). Although a variety of therapeutic options have shown promise in treating MCC, there remains a need for additional therapeutics as well as probes for better understanding MCC. A high-throughput screening campaign was used to assess the ability of > 25,000 synthetic and natural product compounds as well as > 20,000 natural product extracts to affect growth and survival of VN-MCC and VP-MCC cell lines. Sixteen active compounds were identified that have mechanisms of action reported in the literature along with a number of compounds with unknown mechanisms. Screening results with pure compounds suggest a range of potential targets for MCC including DNA damage, inhibition of DNA or protein synthesis, reactive oxygen species, and proteasome inhibition as well as NFκB inhibition while also suggesting the importance of zinc and/or copper binding. Many of the active compounds, particularly some of the natural products, have multiple reported targets suggesting that this strategy might be a particularly fruitful approach. Processing of several active natural product extracts resulted in the identification of additional MCC-active compounds. Based on these results, further investigations focused on natural products sources, particularly of fungal origin, are expected to yield further potentially useful modulators of MCC.

Indexed as

Antineoplastic AgentsBiological ProductsCarcinoma, Merkel CellSkin NeoplasmsCell Line, TumorDrug Screening Assays, AntitumorHumansAntineoplastic AgentsBiological Products

Identifiers

PMID34193920
PMCPMC8245553
OpenAlexW3173600377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.